← 產業報告目錄
Radionuclide Drug Conjugates (RDC) Market Size, Share & Trends Analysis Distribution by Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma) and Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-26頁數 180報告編號 INSIGHTACE-4e5fc59208
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The global Radionuclide Drug Conjugates (RDC) Market is forecasted to witness meaningful expansion over the coming years.
At its core, Radionuclide Drug Conjugates (RDC) pertains to landscape are expandingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and expanding investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radionuclide Drug Conjugates (RDC) Market Snapshot
Chapter 4. Global Radionuclide Drug Conjugates (RDC) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Pipeline Analysis
4.7. Industry Analysis – Porter's Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. By Type, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
5.2.1. Antibody Radionuclide Conjugates (ARC)
5.2.2. Peptide Radionuclide Conjugates (PRC)
5.2.3. Small Molecular Radionuclide Conjugates (SMRC)
Chapter 6. Market Segmentation 2: By Disease Indication Estimates & Trend Analysis
6.1. By Disease Indication & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
6.2.1. Neuroendocrine Tumors
6.2.2. Prostate Cancer
6.2.3. Renal Cell Carcinoma
6.2.4. Others
Chapter 7. Radionuclide Drug Conjugates (RDC) Market Segmentation 5: Regional Estimates &
Trend Analysis
7.1. North America
7.1.1. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Type, 2019-2031
7.1.2. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Disease Indication, 2019-2031
7.1.3. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts by Country, 2019-2031
7.2. Europe
7.2.1. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By Type,
2019-2031
7.2.2. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.2.3. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, 2019-2031
7.3.2. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.3.3. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.4. Latin America
7.4.1. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, (US$ Million) 2019-2031
7.4.2. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, (US$ Million) 2019-2031
7.4.3. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) By Type, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$)
Million) By Disease Indication, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) by Country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Telix Pharmaceuticals Limited
8.2.2. Grand Pharma
8.2.3. Bayer AG
8.2.4. Novartis AG
8.2.5. Lantheus
8.2.6. Curium Pharma
8.2.7. Yantai Lannacheng Biotechnology Co., Ltd
8.2.8. BoomRay Pharmaceuticals
8.2.9. Hengrui Medicine
8.2.10. Yunnan Baiyao Group
8.2.11. Sinotau
8.2.12. SmartNuclide Biopharma
8.2.13. Yuanda Pharmaceutical
8.2.14. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們